Beyond market averages, investors looking for exceptional returns turn to stock picking. Skillful choices in individual stocks have the power to substantially increase your wealth.
After finishing at $31.24 in the prior trading day, Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) closed at $30.95, down -0.93%. In other words, the price has decreased by -$0.93 from its previous closing price. On the day, 0.6 million shares were traded.
Ratios:
Our goal is to gain a better understanding of CRNX by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 22.53 and its Current Ratio is at 22.53. In the meantime, Its Debt-to-Equity ratio is 0.04 whereas as Long-Term Debt/Eq ratio is at 0.04.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stifel on March 25, 2025, initiated with a Buy rating and assigned the stock a target price of $60.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Mar 19 ’25 when Pizzuti Dana sold 2,515 shares for $34.20 per share. The transaction valued at 86,021 led to the insider holds 72,233 shares of the business.
Knight Jeff E. sold 7,162 shares of CRNX for $244,964 on Mar 19 ’25. The Chief Operating Officer now owns 87,491 shares after completing the transaction at $34.20 per share. On Mar 19 ’25, another insider, Betz Stephen F., who serves as the Chief Scientific Officer of the company, sold 5,770 shares for $34.20 each. As a result, the insider received 197,353 and left with 108,588 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8053.89 while its Price-to-Book (P/B) ratio in mrq is 2.31.
Stock Price History:
Over the past 52 weeks, CRNX has reached a high of $62.53, while it has fallen to a 52-week low of $24.10. The 50-Day Moving Average of the stock is -3.39%, while the 200-Day Moving Average is calculated to be -31.54%.
Shares Statistics:
A total of 93.53M shares are outstanding, with a floating share count of 86.71M. Insiders hold about 7.44% of the company’s shares, while institutions hold 105.42% stake in the company.
Earnings Estimates
The current rating of Crinetics Pharmaceuticals Inc (CRNX) reflects the combined expertise of 11.0 analysts actively engaged in assessing its market performance.The consensus estimate for the next quarter is -$1.17, with high estimates of -$1.02 and low estimates of -$1.32.
Analysts are recommending an EPS of between -$4.08 and -$4.77 for the fiscal current year, implying an average EPS of -$4.41. EPS for the following year is -$4.6, with 13.0 analysts recommending between -$3.13 and -$6.17.
Revenue Estimates
A total of 14 analysts have provided revenue estimates for CRNX’s current fiscal year. The highest revenue estimate was $9.14M, while the lowest revenue estimate was $1.7M, resulting in an average revenue estimate of $4.99M. In the same quarter a year ago, actual revenue was $1.04MBased on 14 analysts’ estimates, the company’s revenue will be $44.69M in the next fiscal year. The high estimate is $108.78M and the low estimate is $26M.
